Ideas & Impact › Resources › Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe

Using the Cost Effectiveness of Preventing AIDS Complications (CEPAC)—Pediatric model, the study team examined the clinical benefits, costs, and cost-effectiveness of replacing conventional assays for early infant HIV diagnosis with point-of-care (POC) assays at age 6 weeks in Zimbabwe. Compared with conventional assays, POC assays for early infant HIV diagnosis in Zimbabwe were found to improve survival, extend life expectancy of HIV-exposed infants. They are also more cost-effective than conventional assays.

Explore Related Resources

Search More Resources

Journal Articles

Follow-Up Outcomes of Children, Adolescents, and Young People on Darunavir-Based Third-Line Antiretroviral Therapy

Published October 2024

Background: We assessed clinical outcomes among children, adolescents, and people younger than 25 years on darunavir-based antiretroviral therapy (ART) in 9 sub-Saharan African countries. Setting: Third-line ART centers in Cameroon, Eswatini, Kenya, Lesotho, Nigeria, Rwanda, Uganda, Zambia, and Zimbabwe. Methods: From January 2019 to December 2022, we collected data from a cohort of children, adolescents, and young people […]

Topics:

Adolescents,

Pediatric HIV

Countries:

Cameroon,

Eswatini,

Kenya,

Lesotho,

Nigeria,

Rwanda,

Uganda,

Zambia,

Zimbabwe

Issue Briefs

Building a Future of Health

Published October 2024

An Unspoken Crisis: Children Are Being Left Behind In 2022, one child died every six seconds. The causes of most of those deaths were preventable. This is unacceptable. Whereas countries have the tools and knowledge to end preventable deaths and suffering in children, children face inequalities in access to health care. Parliamentarians play a critical […]

Topics:

Pediatric HIV,

Tuberculosis (TB)

Little girl's hands

Issue Briefs

Building Trust for Global Health

Published October 2024

Most causes of deaths in children could be prevented with effective treatment and interventions that are feasible for implementation, even in resource-constrained settings. However, appropriate medicines to save and improve the lives of infants and children often do not exist, are unavailable, or are not quality assured. This puts children’s lives at risk, hindering the […]

Topics:

HIV,

Pediatric HIV